Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States
Background: The management of muscle-invasive bladder cancer (MIBC) remains challenging. The phase III NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy significantly enhances event-free and overall survival for MIBC patients. However, due to the high cost of durvalumab, assess...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251357519 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839610222284374016 |
|---|---|
| author | Caicong You Jiahao Zhang Jianying Lei Wu Fu Maobai Liu Hongfu Cai Bin Zheng Na Li |
| author_facet | Caicong You Jiahao Zhang Jianying Lei Wu Fu Maobai Liu Hongfu Cai Bin Zheng Na Li |
| author_sort | Caicong You |
| collection | DOAJ |
| description | Background: The management of muscle-invasive bladder cancer (MIBC) remains challenging. The phase III NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy significantly enhances event-free and overall survival for MIBC patients. However, due to the high cost of durvalumab, assessing its cost-effectiveness is crucial. Objective: To compare the cost-effectiveness of durvalumab with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in operable MIBC, from the perspective of U.S. healthcare payers. Design: A model-based pharmacoeconomic evaluation. Method: A Markov model was constructed using data from the NIAGARA trial. Costs and utility were sourced from public databases and literature. Total costs, life-years, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) were evaluated. Sensitivity analysis assessed model robustness. Results: Compared to neoadjuvant chemotherapy alone, the combination of durvalumab with neoadjuvant chemotherapy results in an additional 0.68 QALY, with an incremental cost of $86,485.19. The ICER per QALY is $93,693.79. Sensitivity analysis demonstrated the robustness of the model. Conclusion: From the perspective of U.S. payers, durvalumab combined with neoadjuvant chemotherapy is a cost-effective strategy compared to chemotherapy alone for treating operable MIBC. |
| format | Article |
| id | doaj-art-7f63be1afbba40a3be1f81d06f5d836c |
| institution | Matheson Library |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-7f63be1afbba40a3be1f81d06f5d836c2025-07-29T15:03:35ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-07-011710.1177/17588359251357519Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United StatesCaicong YouJiahao ZhangJianying LeiWu FuMaobai LiuHongfu CaiBin ZhengNa LiBackground: The management of muscle-invasive bladder cancer (MIBC) remains challenging. The phase III NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy significantly enhances event-free and overall survival for MIBC patients. However, due to the high cost of durvalumab, assessing its cost-effectiveness is crucial. Objective: To compare the cost-effectiveness of durvalumab with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in operable MIBC, from the perspective of U.S. healthcare payers. Design: A model-based pharmacoeconomic evaluation. Method: A Markov model was constructed using data from the NIAGARA trial. Costs and utility were sourced from public databases and literature. Total costs, life-years, quality-adjusted life year (QALY), and incremental cost-effectiveness ratio (ICER) were evaluated. Sensitivity analysis assessed model robustness. Results: Compared to neoadjuvant chemotherapy alone, the combination of durvalumab with neoadjuvant chemotherapy results in an additional 0.68 QALY, with an incremental cost of $86,485.19. The ICER per QALY is $93,693.79. Sensitivity analysis demonstrated the robustness of the model. Conclusion: From the perspective of U.S. payers, durvalumab combined with neoadjuvant chemotherapy is a cost-effective strategy compared to chemotherapy alone for treating operable MIBC.https://doi.org/10.1177/17588359251357519 |
| spellingShingle | Caicong You Jiahao Zhang Jianying Lei Wu Fu Maobai Liu Hongfu Cai Bin Zheng Na Li Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States Therapeutic Advances in Medical Oncology |
| title | Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States |
| title_full | Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States |
| title_fullStr | Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States |
| title_full_unstemmed | Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States |
| title_short | Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States |
| title_sort | cost effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the united states |
| url | https://doi.org/10.1177/17588359251357519 |
| work_keys_str_mv | AT caicongyou costeffectivenessofperioperativedurvalumabplusneoadjuvantchemotherapyformuscleinvasivebladdercancerintheunitedstates AT jiahaozhang costeffectivenessofperioperativedurvalumabplusneoadjuvantchemotherapyformuscleinvasivebladdercancerintheunitedstates AT jianyinglei costeffectivenessofperioperativedurvalumabplusneoadjuvantchemotherapyformuscleinvasivebladdercancerintheunitedstates AT wufu costeffectivenessofperioperativedurvalumabplusneoadjuvantchemotherapyformuscleinvasivebladdercancerintheunitedstates AT maobailiu costeffectivenessofperioperativedurvalumabplusneoadjuvantchemotherapyformuscleinvasivebladdercancerintheunitedstates AT hongfucai costeffectivenessofperioperativedurvalumabplusneoadjuvantchemotherapyformuscleinvasivebladdercancerintheunitedstates AT binzheng costeffectivenessofperioperativedurvalumabplusneoadjuvantchemotherapyformuscleinvasivebladdercancerintheunitedstates AT nali costeffectivenessofperioperativedurvalumabplusneoadjuvantchemotherapyformuscleinvasivebladdercancerintheunitedstates |